Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPC-6535 Dose-Finding and Confirmatory Trial in Active Crohn's Disease
jRCT2080220884Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Sep 2009
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of tetomilast in Crohn's disease (3 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Clinical improvement rate. Started Sep 2009; status: completed.
02
Drugs
tetomilast
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on jRCT2080220884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220884.